Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Fiche publication
Date publication
août 2017
Journal
Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse
Tous les auteurs :
Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A
Lien Pubmed
Résumé
Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia. Its role after allogeneic stem cell transplantation (HSCT) has been reported in a few cases with encouraging results.
Mots clés
Adolescent, Adult, Antineoplastic Agents, therapeutic use, Chemotherapy, Adjuvant, Disease-Free Survival, Feasibility Studies, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, therapeutic use, Retrospective Studies, Transplantation, Homologous, Treatment Outcome, Young Adult, fms-Like Tyrosine Kinase 3, genetics
Référence
Cancer. 2017 Aug 1;123(15):2867-2874